Catalogue of Services

What do LS RIs offer the life science community?


The 13 European Life Science Research Infrastructures (LS RIs) have the mission to support cutting-edge science by offering access to their resources and services to European scientists from academia and industry.

Resources and services can simply be consultation, access to experts, but also access to data and biological samples, use of data analysis tools, access to facilities (e.g. highly specialised microscopes) plus support from technicians and much more.

Some of these services are even free to use for institutions location in the RI's member states. 


The Catalogue of Services, which has been developed within the CORBEL project, is the first tool to list the main services of all LS RIs at a glance and it aims to facilitate the utilisation of RI services by researchers from all over the world. The Catalogue of Services as displayed below aims to provide you a basic overview on existing services within distinct thematic fields.


You can either use the Catalogue of Services to identify a single RI to help you with your work or you can create a service pipeline, i.e. using several RIs simultaneously.

What’s your need?

Please select…


Contact person(s): Caitlin Ahern, Fereniki Ioakeimidou

BBMRI-ERIC is a research infrastructure of biobanks and biomolecular resources. Our main goal is to provide expertise and services, advancing the use of European sample collections and its data for the benefit of human health. Our activities are on a non-economic basis and primarily intended for our member countries.

Services provided

BBMRI-ERIC delivers services to their member states in 3 different areas: IT, Quality Management and ELSI

  • Key IT Services

          - Directory (collecting information about biobanks and their sample/data collections)
          - Negotiator (facilitating communication between researchers requesting samples/data
                 from biobanks)
          - Bibbox (toolbox for biobanks, open-source software)
          - MIABIS 2.0 (Community standard for sharing information about biobanks)

  • Key Quality Management Services

          - Knowledge Hub (Consulting on international standards relevant for biobanking and biomedical research; Quality management tasks in EU projects)

  - Training & Support (In-house and online training, university courses, summer schools, short courses, workshops and consulting services covering various quality management systems relevant for biobanking and biomedical research )

- Auditing (The BBMRI-ERIC Self-Assessment Surveys (SAS) help to determine relevant requirements for work processes defined in international standards for biobanking and biomedical research)

- Audit programmes (Remote/on-site) (Quality check mark in Directory (assessment processes, including a remote or on-site audit, can lead to a Q-mark in the BBMRI-ERIC Directory))

  • Key ELSI Services

          - ELSI Helpdesk

          - ELSI Knowledge Base

          - Ethics Check

          - ELSI Policy Monitoring

          - Task Force Societal Issues

          - Task Force GDPR


Services are free for those biobanks that are located in a member state.
For further information please contact us.

Access modes

Access can be on-site or online, dependent on the requested service.
For further information please contact us.

Why work with us

Reproducible data in research is key and in order to achieve that, you need high quality samples and data as starting point. BBMRI-ERIC enables biobanks to work with high quality samples and its associated data and supports controlled access to the wider research community, being a true gateway to health.

Countries involved

Members: AT, BE, BG, CZ, EE, FI, DE, GR, IT, LT, ML, NL, NO, PL, SE, UK
Observer: IARC/WHO, CY, TR, CH

Services contact

Contact person(s): Caitlin Ahern, Fereniki Ioakeimidou


BBMRI-ERIC aims to improve the accessibility and interoperability of the existing comprehensive collections, either population-based or clinical-oriented, of biological samples from different (sub-) populations of Europe or rare diseases. These collections include the attached data on factors such as health status, nutrition, lifestyle, and environmental exposure of the study subjects. In order to fully realize the enormous potential of European biobanks and biomolecular resources for the benefit of European citizens, clinical, ethical and legal experts, the biotech and pharmaceutical industry, patient advocacy groups are collaborating in a participatory governance model (Stakeholder's Forum). The aim is to achieve standards and guidelines that properly balance individual values, such as protection of privacy and informed consent, with shared values of facilitated access to progress in health care and disease prevention.

BBMRI-ERIC will increase efficacy and excellence of European bio-medical research by facilitating fair access to quality-defined human health/disease-relevant biological resources through the inclusion of associated data in an efficient and ethically and legally compliant manner; by reducing the fragmentation of the bio-medical research landscape through harmonisation of procedures, implementation of common standards and fostering high-level collaboration; and by capacity-building in countries with less developed biobanking communities thereby contributing to Europe's cohesion policy and strengthening the ERA.

The EU’s ageing population is resulting in an increase in many of those diseases and consequently an increased healthcare expenditure for senior citizens that place pressure on the sustainability and viability of the EU’s healthcare systems. Through BBMRI-ERIC, biobanks and biomolecular resources shall develop into one of the most important tools for biomedical and clinical discovery. New medical applications, new therapies, new preventive techniques, new diagnostics, personalised or stratified medicine, and new biomedical industries shall evolve to improve socio-economic competitiveness and increase possibilities for equitable healthcare in Europe. The anticipated development shall pave the way for a new research culture in Europe. Expectantly, BBMRI-ERIC will have an impact on partnerships with patients/donors, who know that their own tissues, samples and personal data can yield discoveries and advances in medicine, diagnostics, and therapies. In return, BBMRI-ERIC is taking up the responsibility to make sure that the samples and data that have been entrusted for research are used in the best way possible for the advancement of knowledge, ultimately contributing to improved health care.

The key benefits for users of BBMRI-ERIC are fair access to quality-controlled samples and/or data from population-based, disease-oriented or rare disease biobanks including expertise in handling these biological resources for scientific purposes (ethical, legal and societal issues as well as quality handling). BBMRI-ERIC connects a distributed research infrastructure of biobanks and biomolecular resources for the benefit of the users of such resources. It puts pan-European biobanks on the map and promotes their specific strengths. BBMRI increases the accessibility to quality controlled human biological samples and associated biomedical and biomolecular data in making them findable, accessible, interoperable and reusable. Ultimately, this is key for advancing stratified and precision medicine.

General contact


Contact person(s): Fereniki Ioakeimidou


Contact person(s): Anne-Charlotte Fauvel

EATRIS supports researchers in translating their findings into novel interventions including preventive, diagnostic or therapeutic products up to clinical proof of concept. The infrastructure comprises over 90 leading research institutions in the translational field located in 13 countries across Europe. EATRIS also supports the validation and development of novel tools for precision medicine and translational research in drug development. By providing access to accredited facilities as well as market-oriented expertise, including innovation management, regulatory and health-technology assessment, your validation needs are covered in a one-stop shop.

Services provided

Services offered by EATRIS include

  • support funding applications (Identification of partners for consortium building, assessment of the project plan's impact and innovation potential)
  • translational research facilities and expertise for development of novel biomarkers, diagnostics and therapeutics
  • molecular, functional & hybrid imaging technologies, preclinical models, samples, patient cohorts, GMP manufacturing
  • regulatory and Health Technology Assessment (HTA) expertise
  • advice on intellectual property issues and industry partnering strategy (innovation management)


Costs are calculated on a case by case basis depending on the service required; some services can also be provided as part of funding proposals with EATRIS joining consortia as partner or subcontractor.
For further information please contact us.

Access modes

Services performed can be offered either centrally by the coordination and support team based in Amsterdam or remotely by the EATRIS institutions.

Why work with us

Translating novel biology insights into effective interventions or medical applications is a highly complex process. It requires significant dedicated expertise, facilities and resources. We believe in your medical innovation and we want to support you by bringing together the multi-disciplinary expertise and infrastructure required for optimising your translational trajectory. Working with EATRIS gives greater confidence in the translational feasibility of your project and its impact.

Countries involved


Services contact

Contact person(s): Anne-Charlotte Fauvel


EATRIS, the European infrastructure for translational medicine, provides high quality services in early development of novel therapeutics and diagnostics. Translational research is defined as research that develops promising biomedical innovations 'from bench to bedside,' and conversely brings clinical insights from bedside back to bench.

Translational research is a highly multi-disciplinary and complex undertaking. As a consequence, a major challenge in developing new innovations is understanding what steps need to be taken, and what expertise and technologies are suitable to perform these steps. External researchers in need for academic support will find that EATRIS is able to provide guidance by means of regulatory, clinical and technological expertise available within the infrastructure. Subsequently, EATRIS will match the need with the capabilities within the infrastructure and facilitate collaboration among academics and between academics and companies.

Biomedical inventions frequently fail to pass the “valley of death” for various reasons. EATRIS aims to overcome translational challenges by (1) developing new enabling technologies within the consortium, and (2) making high quality services available for other researchers.

EATRIS strives to accelerate medicines and diagnostics development by utilising cutting-edge, enabling technologies in early translational research. Academic researchers, companies and charities can access clinical expertise and high-end facilities that are available within the 80 top-tier academic centres across Europe comprising EATRIS. Member institutions are selected on the basis of their track record in public-private collaboration in translational development and their multidisciplinary teams of leading academic experts, high-end research facilities, production laboratories and licenses.

We focus on preclinical and early clinical development of drugs, vaccines and diagnostics. Solutions are provided in the fields of advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.

The wide-ranging services portfolio focuses on supporting early decision-making and de-risking of projects. Examples include validation and development of in vitro and in vivo biomarkers for patient stratification, molecular imaging tracers for drug development programmes, GMP manufacturing of cellular therapy products, patient-derived xenograft models, and many more highly specialised capabilities.

General contact


Contact person(s): Anton Ussi

Please note: Most of the RIs are constantly developing their portfolio of services, so if you do not find the service/tool you are looking for, do not hesitate to contact the RI and ask for it!

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 654248.